Condition: Severe Asthma · Sponsor: Kinaset Therapeutics Inc
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Research site | Lancaster, California, United States | Recruiting |
| Research site | San Jose, California, United States | Recruiting |
| Research site | Brandon, Florida, United States | Not Yet Recruiting |
| Research site | Miami, Florida, United States | Recruiting |
| Research site | Tampa, Florida, United States | Recruiting |
| Research site | Chicago, Illinois, United States | Not Yet Recruiting |
| Research site | Kansas City, Missouri, United States | Not Yet Recruiting |
| Research site | Charlotte, North Carolina, United States | Recruiting |
| Research site | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
| Research site | Rock Hill, South Carolina, United States | Recruiting |
| Research site | Dallas, Texas, United States | Recruiting |
| Research site | Houston, Texas, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07532265